{"certainAgreement":{"piSponsorEmployee":true},"limitationsAndCaveats":{"description":"The trial was amended to exclude fibrosarcoma after only one patient was accrued while the other cohorts had completed 75% or more of their planned accrual. Only patients with liposarcoma, leiomyosarcoma, or MFH were enrolled after this amendment."},"pointOfContact":{"email":"alberto.chiappori@moffitt.org","organization":"H. Lee Moffitt Cancer Center and Research Institute","phone":"813-745-2158","title":"Alberto Chiappori, M.D."}}